5-(溴甲基)吡嗪-2-羧酸甲酯 | 193966-70-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-(溴甲基)吡嗪-2-羧酸甲酯
• 英文名称: methyl 5-(bromomethyl)pyrazine-2-carboxylate
• CAS: 193966-70-0
• 化学式: C₇H₇BrN₂O₂
• 分子量: 231.049
• InChiKey: OIGRHUBIDWZLHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P501,P260,P270,P264,P280,P303+P361+P353,P301+P330+P331,P363,P301+P312+P330,P304+P340+P310,P305+P351+P338+P310,P405
• 危险品运输编号：
  1759
• 危险性描述：
  H302,H314

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  5-甲基吡嗪-2-羧酸甲酯	methyl 5-methylpyrazine-2-carboxylate	41110-33-2	C7H8N2O2	152.153
  5-(羟甲基)吡嗪-2-甲酸甲酯	methyl 5-(hydroxymethyl)pyrazine-2-carboxylate	1262803-64-4	C7H8N2O3	168.152
  吡嗪-2,5-二羧酸二甲酯	dimethyl Pyrazine-2,5-dicarboxylate	13051-89-3	C8H8N2O4	196.163
  5-甲基吡嗪-2-羧酸	2-methylpyrazin-5-carboxylic acid	5521-55-1	C6H6N2O2	138.126
  2,5-吡嗪二羧酸	2,5-pyrazinedicarboxylic acid	122-05-4	C6H4N2O4	168.109

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	5-(hydroxymethyl)pyrazine-2-carboxylic acid	——	C6H6N2O3	154.125
  ——	methyl 5-[(1-Pyrrolidinyl)methyl]pyrazine-2-carboxylate	193966-71-1	C11H15N3O2	221.259
  ——	5-(azidomethyl)pyrazine-2-carboxylic acid	——	C6H5N5O2	179.138

反应信息

• 作为反应物：
  描述：

  5-(溴甲基)吡嗪-2-羧酸甲酯 在 氢氧化钾 、 三乙胺 作用下， 以 水 、 乙腈 为溶剂， 反应 22.25h， 生成 5-Cyclopropylaminomethyl-pyrazine-2-carboxylic acid
  参考文献：
  名称：

  Discovery of Further Pyrrolidine trans-Lactams as Inhibitors of Human Neutrophil Elastase (HNE) with Potential as Development Candidates and the Crystal Structure of HNE Complexed with an Inhibitor (GW475151)

  摘要：

  Described herein is a modern approach to the rapid preparation and evaluation of compounds as potential back-up drug candidates. GW311616A, 1, a derivative of pyrrolidine trans-lactams, has previously been described as a potent, orally active inhibitor of human neutrophil elastase (HNE) for the treatment of respiratory disease. These properties made it a suitable candidate for development. Described here is the discovery of three further derivatives of pyrrolidine trans-lactams, which fulfill the criteria required for back-up candidates 28, 29, and 32. These include increased activity in inhibiting HNE in human whole blood (HWB) and comparable pharmacokinetic properties, in particular clearance, in two species. To provide a rapid assessment of clearance, cassette dosing in dog was used. Modern array techniques, including the synthesis of mixtures, were used to synthesize compounds rapidly. Having selected three potential compounds as back-up candidates, they were prepared as single enantiomers and profiled in in vitro and in vivo assays and evaluated pharmacokinetically in rat and dog. These compounds are highly potent and selective HNE inhibitors, with a prolonged pharmacodynamic action. Pharmacokinetically, these compounds are comparable with I while they are more potent in HWB. Compound 28, however, has a higher clearance. One of these compounds, 32, was cocrystallized with HNE, and features of this structure are described and compared with the cocrystal structure of 1 in porcine pancreatic elastase.

  DOI：

  10.1021/jm020881f
• 作为产物：
  描述：

  5-(羟甲基)吡嗪-2-甲酸甲酯 在 N-溴代丁二酰亚胺(NBS) 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 以56.5%的产率得到5-(溴甲基)吡嗪-2-羧酸甲酯
  参考文献：
  名称：

  TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A PYRIDINE OR PYRAZINE MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR

  摘要：

  根据公式(I)结构的化合物，其中R1和Ar的定义如本文所述，是Toll样受体7（TLR7）的激动剂，可用作刺激免疫系统的辅助剂。一些这样的化合物可以用于与靶向递送到预期作用的器官或组织的结合物中。

  公开号：

  US20190055245A1
• 作为试剂：
  描述：

  5-甲基吡嗪-2-羧酸甲酯 、 溴 在 溶剂黄146 、 乙酸乙酯 、 silica gel 、 5-(溴甲基)吡嗪-2-羧酸甲酯 作用下， 以 溶剂黄146 为溶剂， 反应 0.75h， 以to afford the title compound methyl 5-(bromomethyl)pyrazine-2-carboxylate (0.3 g, 40%) as a brownish liquid的产率得到5-(溴甲基)吡嗪-2-羧酸甲酯
  参考文献：
  名称：

  N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A

  摘要：

  本发明公开了选择性负调节含有NR2A亚基的NMDA受体的化合物、包含该化合物的制药组合物以及使用该化合物治疗疾病的方法。

  公开号：

  US20150141433A1

文献信息

• Antithrombotic diamines
  申请人：Eli Lilly and Company

  公开号：US06025382A1

  公开（公告）日：2000-02-15

  This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula I as defined herein. It also provides novel compounds of formula I, processes and intermediates for their preparation, and pharmaceutical formulations comprising the novel compounds of formula I.

  该应用涉及将I式中所定义的二胺用作凝血酶抑制剂、凝血抑制剂和血栓栓塞性疾病药剂。它还提供了I式的新化合物，其制备方法和中间体，以及包含这些新化合物的药物配方。
• 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS
  申请人：Hunziker Daniel

  公开号：US20100249139A1

  公开（公告）日：2010-09-30

  The present invention relates to compounds of formula I wherein R 1a to R 1e and R 2 to R 5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.

  本发明涉及以下式I的化合物 其中R 1a 至R 1e 和R 2 至R 5 如描述和权利要求中所定义，并且其药学上可接受的盐。这些化合物是糖皮质激素受体拮抗剂，可用于治疗和/或预防疾病，如糖尿病、血脂异常、肥胖、高血压、心血管疾病、肾上腺失调或抑郁症。
• [EN] 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS DE 1,3,4-OXADIAZOLE SULFONAMIDE SERVANT D'INHIBITEUR DE L'HISTONE DÉSACÉTYLASE 6, ET COMPOSITION PHARMACEUTIQUE COMPRENANT CEUX-CI
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP

  公开号：WO2017018803A1

  公开（公告）日：2017-02-02

  The present invention relates to novel compounds represented by the formula I having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. (I) The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases.

  本发明涉及具有组蛋白去乙酰化酶6（HDAC6）抑制活性的新化合物，其立体异构体或药学上可接受的盐，其用于制备治疗药物，含有相同化合物的药物组合物，使用该组合物治疗疾病的方法，以及制备新化合物的方法。根据本发明，这些新化合物、其立体异构体或药学上可接受的盐具有组蛋白去乙酰化酶（HDAC）抑制活性，并且对于预防或治疗HDAC6介导的疾病有效。
• [EN] PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV<br/>[FR] COMPOSES PYRIDINES UTILISES COMME INHIBITEURS DE DIPEPTIDYLE PEPTIDASE IV
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2005042488A1

  公开（公告）日：2005-05-12

  A compound represented by the formula wherein R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted hydroxy group; R3 is an optionally substituted aromatic group; R4 is an optionally substituted amino group; L is a divalent chain hydrocarbon group; Q is a bond or a divalent chain hydrocarbon group; and X is a hydrogen atom, a cyano group, a nitro group, an acyl group, a substituted hydroxy group, an optionally substituted thiol group, an optionally substituted amino group or an optionally substituted cyclic group; provided that when X is an ethoxycarbonyl group, then Q is a divalent chain hydrocarbon group. The compound has a peptidase inhibitory action, is useful as an agent for the prophylaxis or treatment of diabetes and the like, and is superior in efficacy, duration of action, specificity, lower toxicity and the like.

  该化合物的化学式表示为其中R1和R2相同或不同，每个都是可选择取代的碳氢基团或可选择取代的羟基团；R3是可选择取代的芳香基团；R4是可选择取代的氨基团；L是二价链状碳氢基团；Q是键或二价链状碳氢基团；X是氢原子、氰基、硝基、酰基、取代的羟基团、可选择取代的硫醇基团、可选择取代的氨基团或可选择取代的环状基团；但当X是乙氧羰基团时，Q为二价链状碳氢基团。该化合物具有肽酶抑制作用，可用作糖尿病等疾病的预防或治疗药物，并在功效、作用持续时间、特异性、毒性较低等方面具有优越性。
• NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME
  申请人：Kureha Chemical Industry Co., Ltd.

  公开号：EP1273571A1

  公开（公告）日：2003-01-08

  The present invention provides novel compounds having antiviral activities and antiviral drugs containing the compounds as the active ingredient. The compounds are shown by the following general formula (1), wherein typically A1 and A2 are each guanidine or a group of the general fomula (ia) ; A3 is a mono- or poly-cyclic heteroaromatic ring contining 1 or 2 heteroatoms ; B1 is a single bond or alkylene group; R1 is hydrogen or alkyl group; W is an alkylene having 2-3 carbons, a cycloalkylene having 5-10 carbons, aromatic ring having 6-10 carbons, or a heteroaromatic ring having 5-10 carbons; y is C(=O)-; x is -C(=O)-NH-; n1 is an integer of 1-2; n2 is an integer of 2-3; D is a substituent selected from among various groups.

  本发明提供了具有抗病毒活性的新化合物以及含有这些化合物作为活性成分的抗病毒药物。这些化合物由以下一般式（1）所示，其中通常A1和A2分别是胍或一般式（ia）的基团；A3是含有1个或2个杂原子的单环或多环杂芳环；B1是单键或烷基基团；R1是氢或烷基基团；W是具有2-3个碳的烷基、具有5-10个碳的环烷基、具有6-10个碳的芳香环或具有5-10个碳的杂芳环；y是C(=O)-；x是-C(=O)-NH-；n1是1-2的整数；n2是2-3的整数；D是从各种基团中选择的取代基。